ContributeQuick Hits

Over the years there have been attempts at standardizing care for the patient with inflammatory bowel disease (IBD). I was the director of AGA’s initiative to establish quality metrics for the care of patients with IBD in 2011. Subramanian and Triadafilopoulos published a review in 2016,1 and Berry and Melmed published an excellent review this […]

ContributeDebates

This is half of a two-part debate — read the opposing argument.  Following the introduction of infliximab in 1998, two additional tumor necrosis factor antagonists (i.e., adalimumab, certolizumab pegol), the anti- integrin vedolizumab and ustekinumab (a monoclonal directed to interleukin 12 and 23) were approved for the management of inflammatory bowel disease. Biologics have greatly […]

Debates

This is half of a two-part debate — read the opposing argument.  The safety and effectiveness of anti–tumor necrosis factor (TNF) therapy for the treatment of inflammatory bowel disease (IBD) has been well established for decades. Therefore, introducing anti-TNF biosimilars to the marketplace does not represent a new mode of treatment for patients with IBD, […]

Contribute

The inaugural Crohn’s & Colitis Congress™ (Jan. 18-20, 2018, Las Vegas, Nevada) gathered more than 1,250 inflammatory bowel disease (IBD) health care professionals and featured more than 250 abstracts — with the goal of advancing research and transforming the care of IBD patients. The Crohn’s & Colitis Congress is a new partnership between the Crohn’s […]

Debates

The last decade has witnessed significant expansion in our understanding of inflammatory bowel disease (IBD) therapies and their pharmacological characteristics. This improved knowledge, along with the paradigm shift in IBD management — evolving from merely symptom control to blocking disease progression and preventing bowel damage — has resulted in the emergence of several treatment concepts […]

Debates

In almost all areas of medicine, we accept a role for therapeutic drug monitoring. Whether we consider digoxin levels or vancomycin and cyclosporine troughs, the principles remain the same — there is a range wherein the drug is effective and also one in which there is toxicity. For the purposes of this treatise, we posit […]

Quick Hits

With the recent approvals of infliximab biosimilars, CT-P13 and SB2, and adalimumab biosimilar, ABP 501, by the U.S. FDA, the landscape of available anti-tumor necrosis factor (TNF) therapies for the treatment of inflammatory bowel disease (IBD) is changing right before our eyes. To understand the implications of this change, it is important to consider several […]

Quick Hits

The link between chronic inflammatory bowel disease (IBD) and colon cancer is well established. Colorectal cancer (CRC) is increased in patients with IBD involving at least one-third of the colon, and it is important to remember that it is the same for Crohn’s disease and ulcerative colitis. Classically, the risk of CRC was estimated to […]

Plan B
Quick Hits

 Medical treatment options for patients with inflammatory bowel diseases (IBD) — Crohn’s disease and ulcerative colitis (UC) — have rapidly expanded with several different classes of medications now available. Traditionally, conventional therapy has consisted of mesalamine, steroids and immunomodulators, but in the era of biologic therapy, new options are available. However, variability remains in approaches […]

Quick Hits

Clinicians may have noticed that pouchitis is no longer a simple, antibioticresponsive disease. Over the years, we have seen a growing number of patients with chronic antibiotic-refractory pouchitis (CARP). While the Asian “carp” fish has invaded our rivers and lakes, the CARP disease has become a threat to the wellness and even survival of the […]